JP2018536705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536705A5 JP2018536705A5 JP2018541596A JP2018541596A JP2018536705A5 JP 2018536705 A5 JP2018536705 A5 JP 2018536705A5 JP 2018541596 A JP2018541596 A JP 2018541596A JP 2018541596 A JP2018541596 A JP 2018541596A JP 2018536705 A5 JP2018536705 A5 JP 2018536705A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- amino
- methyl
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000001441 melanoma Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 5
- 208000005777 Lupus Nephritis Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 206010038389 Renal cancer Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000026278 immune system disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 201000010982 kidney cancer Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims 4
- 230000005784 autoimmunity Effects 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 4
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000009137 Behcet syndrome Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000011200 Kawasaki disease Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010000269 abscess Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 201000011066 hemangioma Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims 3
- 210000000106 sweat gland Anatomy 0.000 claims 3
- 206010043207 temporal arteritis Diseases 0.000 claims 3
- 208000008732 thymoma Diseases 0.000 claims 3
- 230000005747 tumor angiogenesis Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 101100001794 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aps-2 gene Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000000642 iatrogenic effect Effects 0.000 claims 2
- -1 imidazo [1,5-a] pyrazin-1-yl Chemical group 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- LZIJKEIPCFEOLH-UHFFFAOYSA-N n-pyridin-2-ylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=N1 LZIJKEIPCFEOLH-UHFFFAOYSA-N 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 201000006958 oropharynx cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 210000005008 immunosuppressive cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- KUAULQNJJCPMMR-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)benzamide Chemical compound N1=CC(C)=CC=C1NC(=O)C1=CC=CC=C1 KUAULQNJJCPMMR-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000002707 regulatory b cell Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252420P | 2015-11-06 | 2015-11-06 | |
| US62/252,420 | 2015-11-06 | ||
| US201562261228P | 2015-11-30 | 2015-11-30 | |
| US62/261,228 | 2015-11-30 | ||
| PCT/IB2016/056661 WO2017077507A1 (en) | 2015-11-06 | 2016-11-04 | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536705A JP2018536705A (ja) | 2018-12-13 |
| JP2018536705A5 true JP2018536705A5 (enExample) | 2019-11-21 |
| JP6890602B2 JP6890602B2 (ja) | 2021-06-18 |
Family
ID=57286764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541596A Active JP6890602B2 (ja) | 2015-11-06 | 2016-11-04 | ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10736893B2 (enExample) |
| EP (2) | EP3371189A1 (enExample) |
| JP (1) | JP6890602B2 (enExample) |
| CN (1) | CN108602827B (enExample) |
| MA (1) | MA43162A (enExample) |
| WO (1) | WO2017077507A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6890602B2 (ja) * | 2015-11-06 | 2021-06-18 | アセルタ ファーマ ビー．ブイ． | ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 |
| ES2878973T3 (es) * | 2016-06-30 | 2021-11-19 | Hangzhou Bangshun Pharmaceutical Co Ltd | Derivado de fenilo de imidazopiridinamina y uso del mismo |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| CN110494433B (zh) | 2017-03-22 | 2023-03-17 | 廖细斌 | 布鲁顿酪氨酸激酶抑制剂 |
| US10800787B2 (en) | 2017-04-20 | 2020-10-13 | Apotex Inc. | Process for the preparation of acalabrutinib |
| WO2019013562A1 (ko) * | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| KR102384924B1 (ko) * | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| US11161851B2 (en) * | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
| CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
| CN108129483B (zh) * | 2018-01-26 | 2019-06-04 | 成都施贝康生物医药科技有限公司 | 一种btk抑制剂及其应用 |
| CN108250186B (zh) * | 2018-02-07 | 2020-01-14 | 杭州科巢生物科技有限公司 | Acalabrutinib及其中间体的合成方法 |
| KR102106821B1 (ko) | 2018-04-27 | 2020-05-06 | 재단법인대구경북과학기술원 | 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| CN109053780B (zh) * | 2018-07-05 | 2020-09-29 | 浙江合聚生物医药有限公司 | 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法 |
| EA202190557A1 (ru) | 2018-08-29 | 2021-07-13 | Асерта Фарма Б.В. | СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА |
| KR102833011B1 (ko) * | 2018-09-14 | 2025-07-14 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 푸로[3,4-b]피롤-함유 BTK 억제제 |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020225831A1 (en) * | 2019-05-09 | 2020-11-12 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide |
| CN113993871B (zh) * | 2019-07-12 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 含有5-氮杂螺庚烷的btk抑制剂 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20230027201A (ko) * | 2020-06-19 | 2023-02-27 | 아세르타 파마. 비.브이. | 아칼라브루티닙 말레산염 투약 형태 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| EP2029163A4 (en) | 2006-06-14 | 2010-08-11 | Imclone Llc | LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES |
| US7894450B2 (en) | 2007-12-31 | 2011-02-22 | Nortel Network, Ltd. | Implementation of VPNs over a link state protocol controlled ethernet network |
| KR101653842B1 (ko) | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| LT2734522T (lt) * | 2011-07-19 | 2019-02-11 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015110923A2 (en) * | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| US20170231995A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
| JP6890602B2 (ja) * | 2015-11-06 | 2021-06-18 | アセルタ ファーマ ビー．ブイ． | ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 |
-
2016
- 2016-11-04 JP JP2018541596A patent/JP6890602B2/ja active Active
- 2016-11-04 WO PCT/IB2016/056661 patent/WO2017077507A1/en not_active Ceased
- 2016-11-04 MA MA043162A patent/MA43162A/fr unknown
- 2016-11-04 US US15/773,846 patent/US10736893B2/en active Active
- 2016-11-04 EP EP16794751.4A patent/EP3371189A1/en not_active Withdrawn
- 2016-11-04 EP EP21151227.2A patent/EP3865485A1/en not_active Withdrawn
- 2016-11-04 CN CN201680077913.0A patent/CN108602827B/zh active Active
-
2020
- 2020-06-30 US US16/917,222 patent/US11110088B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536705A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2016522232A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| JP2016533379A5 (enExample) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2016040288A5 (enExample) | ||
| JP2019527230A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2014533695A5 (enExample) | ||
| JP2017502092A5 (enExample) | ||
| JP2016505586A5 (enExample) | ||
| JP2016516791A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2011509309A5 (enExample) | ||
| TW201031653A (en) | Protein kinase inhibitors | |
| JP2015518894A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2015524472A5 (enExample) |